| Report | Question ID | Question | Discussion | Answer | Cancer Site Category | Data Item Category | Year |
|---|---|---|---|---|---|---|---|
|
|
20010033 | Grade, Differentiation--Breast: 1) If Van Nuys nuclear grade 2 is the only grade given for an in situ breast primary, would it be coded as a 3-component system (e.g., 2/3 = 3)? 2) Is there a way of determining grade if only the total Van Nuys Prognostic index score is given (e.g., score 7/9)? |
1. Code Van Nuys grade 2 as code 2 [Grade 2] in the Grade, Differentiation field. 2. Code Van Nuys score of 7 as 9 [Cell type not determined, not stated or not applicable] in the Grade, Differentiation field.
Currently, there is no conversion from the total Van Nuys score to grade because "grade" represents only one of the three Van Nuys factors that make up the total score. The other factors are tumor size and margin. The grade represents from 1 to 3 points within the total Van Nuys score. The total score can be between 3 and 9. |
Breast | N/A | 2001 | |
|
|
20010075 | Histology (Pre-2007): What code is used to represent the histology "adenocarcinoma with a mucinous focus"? See discussion. | Could 8480/3 [mucinous adenocarcinoma] be used to code histology? | For tumors diagnosed prior to 2007:
Code the Histology field to 8140/3 [adenocarcinoma, NOS]. "Focus" does not indicate the majority of tumor per rule C2 on page 2 of the Coding Complex Morph Dx's. The tumor must be at least 50% mucinous, mucin producing, or signet ring to be coded to the specific histology.
We code to the more specific term if there are no qualifying or modifying terms such as: focally, focus, predominantly. If any qualifying words are used, the C1 rule applies, which is to code to the majority of tumor.
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
N/A | Histology | 2001 |
|
|
20010128 | Multiple Primaries (Pre-2007)--Bladder/Prostatic Urethra: When invasive TCC of the bladder and TCC in-situ of the prostatic urethra are diagnosed at the same time, are they reportable as two primaries? See discussion. | There is no direct extension of tumor from the bladder to the urethra. According to the SEER rules for determining separate primaries, bladder (C67) and urethra (C68) are separate sites. However, it seems that TCC in the bladder and urethra should be reported as a single primary. | For tumors diagnosed prior to 2007:
This is one primary. Mucosal spread of in situ cancer from a hollow organ (bladder) into another hollow organ (prostatic urethra) is coded as a single primary.
This type of mucosal spread of tumor is sometimes referred to as "intramucosal extension" or " in situ component extending to." Mucosal spread can also be expressed as a statement of an invasive component in one organ with adjacent or associated in situ carcinoma in a contiguous organ with the same type of epithelium.
This case represents an invasive bladder tumor with in situ extension to the prostatic urethra. A tumor that is breaking down can be invasive in the center with in situ cancer at its margins. Occasionally, the in situ margin can move into a contiguous organ with the same type of epithelium.
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
Bladder | N/A | 2001 |
|
|
20010055 | EOD-Lymph Nodes--Breast: Are lymph nodes described as being either "keratin positive" or "keratin positive for metastasis" to be coded as involved lymph nodes? | For cases diagnosed between 1998-2003:
Lymph nodes that are only "keratin positive" would not be coded as involved lymph nodes. The pathologist uses this expression to mean that the nodes stained positive for keratin that does not mean they are also involved with cancer.
However, if the pathologist uses these stains to make a definitive diagnosis of metastatic carcinoma (i.e., uses the expression "keratin positive for metastasis"), then code the nodes as involved. |
Breast | N/A | 2001 | |
|
|
20010084 | EOD-Size of Primary Tumor: Can you code the known size of the residual tumor in a further resected specimen if the size of the tumor in a prior excisional biopsy is unknown? See discussion. | Excisional biopsy is done prior to admission and the tumor size is unknown. Pt is admitted for a mastectomy and the residual tumor size is 5 mm. | For cases diagnosed between 1998-2003:
Code the EOD-Size of Primary Tumor field to 999 [unknown]. The majority of the tumor would have been removed during excisional biopsy and it is possible that the tumor could have been quite large. |
N/A | N/A | 2001 |
|
|
20010168 | Histology (Pre-2007): What code is used to represent the histology "adenocarcinoma, undifferentiated, with sarcomatoid features"? See discussion. |
Is the case more accurately coded with histology of adenosarcoma [8933/34] or adenocarcinoma, undifferentiated [8140/34]? Should "sarcomatoid" be interpreted as sarcoma? | For tumors diagnosed prior to 2007:
Code the Histology field to 8140/34 [adenocarcinoma, undifferentiated]. Sarcomatoid means sarcoma-like and should not be used in coding histology.
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
N/A | Histology | 2001 |
|
|
20010091 | Surgical Procedure of Other Site: Is the excision of a distant lymph node or a fine needle aspirate (FNA) of a distant lymph node coded as a Surgical Procedure of Other Site, even though they are performed for diagnostic purposes and not intended as treatment? | For cases diagnosed 1/1/2003 and after: Code the Surgical Procedure of Other Site field to 3 [Non-primary surgical procedure to distant lymph nodes] for an excision of a distant lymph node because it is a surgical procedure. However, if only a fine needle aspirate of a distant lymph node is done, code this field to 0 [None].
Fine needle aspirates of regional lymph nodes are the only FNA biopsies to be coded in a surgery field (Scope of Regional Lymph Node Surgery field). In addition, FNA biopsies of regional nodes are also included in the EOD-Number of Positive Regional and Examined Lymph Nodes fields. |
Lymph nodes | First course treatment | 2001 | |
|
|
20010136 | Reason no treatment/Surgery of Primary Site: Does the "Reason for No Cancer-Directed Therapy" field only relate to the "Surgery of Primary Site" field? If so, for what diagnosis years is that effective? Have SEER's coding guidelines changed over time? See discussion. | Whenever a surgical procedure is performed that results in a non 0 or 9 code in any one of the Surgery fields, should the Reason for No Site-Specific Surgery field be coded to 0 [Cancer-directed surgery performed]? | For cases diagnosed 2003 and forward: The field "Reason for No Surgery of Primary Site" applies only to surgery of primary site. This is a change from the pre-2003 instructions. | N/A | Reason no treatment, Surgery of Primary Site | 2001 |
|
|
20010036 | Histology (Pre-2007)--Breast: What code is used to represent the histology for a single lesion with "metaplastic carcinoma" and the majority of tumor has sarcomatoid appearance? Squamous cell carcinoma and high grade intraductal carcinoma are also present. Is the term "sarcomatoid" equivalent to sarcoma? | For tumors diagnosed prior to 2007:
For cases diagnosed on or after 1/1/2001: Code the Histology field to 8575/3 [metaplastic carcinoma]. Sarcomatoid is not coded as sarcoma.
The terms metaplastic carcinoma, squamous cell carcinoma and intraductal carcinoma are used, but only the metaplastic and squamous cell carcinomas are invasive. Metaplastic, loosely defined, means tissue that is not normal.
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
Breast | Histology | 2001 | |
|
|
20010103 | Histology (Pre-2007)--Breast: Are diagnoses of "infiltrating duct and mucinous carcinoma" and "duct carcinoma, mucinous type" both coded to the histology code of 8523/3? | For tumors diagnosed prior to 2007:
Code "Infiltrating duct and mucinous carcinoma" to 8523/3 [Infiltrating duct mixed with other types of carcinoma] according to the instructions for coding a single tumor with complex histology in Appendix C of the 2004 SEER manual. Assign code 8523/3 when the diagnosis is duct carcinoma mixed with another type of carcinoma. Look for "and" or "mixed" in the diagnosis. Code the Histology field for a "ductal carcinoma, mucinous type" to 8480/3 [Mucinous carcinoma]. The instructions for coding a single tumor with complex histology are to code the specific type if the diagnosis is "Duct carcinoma, _____ type."
For tumors diagnosed 2007 or later, refer to the MP/H rules. If there are still questions about how this type of tumor should be coded, submit a new question to SINQ and include the difficulties you are encountering in applying the MP/H rules. |
Breast | Histology | 2001 |
Home
